Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vemircopan by Alexion Pharmaceuticals for Lupus Nephritis: Likelihood of Approval
Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase...
Vemircopan by Alexion Pharmaceuticals for Systemic Lupus Erythematosus: Likelihood of Approval
Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...
Vemircopan by Alexion Pharmaceuticals for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): Likelihood of Approval
Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Membranoproliferative Glomerulonephritis Type II (Dense Deposit...
Vemircopan by Alexion Pharmaceuticals for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Vemircopan is under clinical development by Alexion Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease). According to...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Vemircopan?
Vemircopan is a small molecule commercialized by AstraZeneca, with a leading Phase II program in IgA Nephropathy (Berger's Disease). According...